Effectiveness of Pharmacist-Led Interventions for Blood Pressure Control in Hospital and Hospital-Linked Settings: A Systematic Review and Meta-analysis A Systematic Review and Meta Analysis
Main Article Content
Abstract
Hypertension remains a major contributor to cardiovascular morbidity and mortality, while evidence on pharmacist-led care in hospital and hospital-linked settings is fragmented. This systematic review and meta-analysis evaluated the effects of clinical pharmacist-led interventions on blood pressure and related outcomes in adults with hypertension. PubMed and Scopus were searched through 23 November 2025. Five studies were included: three randomized controlled trials, one quasi-randomized controlled trial, and one nonrandomized before-after study. Interventions comprised structured education, medication review and optimization, medication therapy management, home blood pressure monitoring, and follow-up. Narrative findings generally favored pharmacist-led care for blood pressure, medication adherence, hypertension knowledge, and resolution of drug-related problems. Two controlled trials, one randomized and one quasi-randomized, contributed to the exploratory meta-analysis. Pharmacist-led interventions reduced systolic blood pressure by a pooled mean difference of -5.27 mmHg (95% CI -7.23 to -3.31; I² = 0%). The pooled diastolic blood pressure effect favored intervention but was not statistically significant (mean difference -4.21 mmHg; 95% CI -9.80 to 1.38; I² = 85.1%). Interpretation is limited by the small number of pooled studies, heterogeneous interventions, attrition, and risk of bias. Pharmacist-led interventions may improve systolic blood pressure and medication-management outcomes, but additional rigorously designed trials with standardized interventions and outcome reporting are needed.
Article Details

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The authors retain the copyright and grant the journal the right of first publication simultaneously under the Creative Commons Attribution License. This license allows others to share the work with proper acknowledgment of authorship and initial publication in this journal. Authors are permitted and encouraged to deposit their articles in institutional repositories, on their personal websites, or in other online repositories after the article has been published in JSFK.
References
[1] Huynh BH, Vo HT, Pham ATK, et al. Effect of pharmacist-led interventions on hypertension-related knowledge, medication adherence, and blood pressure control: a multicenter randomized controlled trial in Vietnam. J Am Coll Clin Pharm. 2024;7(6):544-553. doi:10.1002/jac5.1955
[2] Li N, Song JF, Zhang MZ, Lv XM, Hua HL, Chang YL. Impact of medication therapy management service model on patients with multimorbidity and hypertension: a pilot randomized controlled trial. BMC Geriatr. 2023;23:10. doi:10.1186/s12877-023-03725-4
[3] Okoro RN, Ummate I, Ohieku JD, Yakubu SI, Adibe MO. The impact of pharmacist-led interventions on blood pressure control among patients with chronic kidney disease: a randomized controlled trial. J Am Coll Clin Pharm. 2022;5(10):1062-1074. doi:10.1002/jac5.1677
[4] Zhou X, Zhang X, Gu N, Cai W, Feng J. Barriers and facilitators of medication adherence in hypertension patients: a meta-integration of qualitative research. J Patient Exp. 2024;11:23743735241241176. doi:10.1177/23743735241241176
[5] Hamrahian SM, Maarouf OH, Fulop T. A critical review of medication adherence in hypertension: barriers and facilitators clinicians should consider. Patient Prefer Adherence. 2022;16:2749-2757. doi:10.2147/PPA.S368784
[6] Migliozzi DR, Zullo AR, Collins C, Elsaid KA. Achieving blood pressure control among renal transplant recipients by integrating electronic health technology and clinical pharmacy services. Am J Health Syst Pharm. 2015;72(22):1987-1992. doi:10.2146/ajhp140810
[7] Reeves L, Robinson K, McClelland T, Adedoyin C, Broeseker AE, Adunlin G. Pharmacist interventions in the management of blood pressure control and adherence to antihypertensive medications: a systematic review of randomized controlled trials. J Pharm Pract. 2021;34(3):480-492. doi:10.1177/0897190020903573
[8] Matsumoto N, Nakai T, Sakakibara M, Aimiya Y, Sugiura S, Lee JK, Yamada S, Mizuno T. Remote follow-up by pharmacists for blood pressure control in patients with hypertension: a systematic review and a meta-analysis of randomized controlled trials. Sci Rep. 2024;14(1):2535. doi:10.1038/s41598-024-52894-8
[9] Rattanavipanon W, Chaiyasothi T, Puchsaka P, et al. Effects of Pharmacist Interventions on Cardiovascular Risk Factors and Outcomes: An Umbrella Review of Meta‐analysis of Randomized Controlled Trials. Br J Clin Pharmacol. Published online 2022. doi:10.1111/bcp.15279
[10] Gastens V, Tancredi S, Bonnan D, et al. Pharmacist Interventions to Improve Hypertension Management Among Patients With Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. BMC Health Serv Res. Published online 2025. doi:10.1186/s12913-025-13461-7
[11] Alshehri AA, Jalal Z, Cheema E, Haque S, Jenkins D, Yahyouche A. Impact of the Pharmacist‐led Intervention on the Control of Medical Cardiovascular Risk Factors for the Primary Prevention of Cardiovascular Disease in General Practice: A Systematic Review and Meta‐analysis of Randomised Controlled Trials. Br J Clin Pharmacol. Published online 2020. doi:10.1111/bcp.14164
[12] Bryant KB, Rao AS, Cohen LP, Dandan N, Kronish IM, Barai N, et al. Effectiveness and cost-effectiveness of team-based care for hypertension: a meta-analysis and simulation study. Hypertension. 2023;80(6):1199-1208. doi:10.1161/HYPERTENSIONAHA.122.20292
[13] Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71
[14] Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.5. Cochrane; 2024. Available from: https://training.cochrane.org/handbook
[15] Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898
[16] Sterne JAC, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. doi:10.1136/bmj.i4919
[17] Paudel N, Shrestha S, Marasine NR, et al. Impact of hospital pharmacist-delivered individualised pharmaceutical service intervention on clinical and patient-reported outcomes in patients with hypertension: a randomised controlled trial. Eur J Hosp Pharm. 2023;30(6):316-321. doi:10.1136/ejhpharm-2020-002512
[18] Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397(10285):1625-1636. doi:10.1016/S0140-6736(21)00590-0
[19] Katz ME, Mszar R, Grimshaw AA, et al. Digital health interventions for hypertension management in US populations experiencing health disparities: a systematic review and meta-analysis. JAMA Netw Open. 2024;7(2):e2356070. doi:10.1001/jamanetworkopen.2023.56070
[20] Torres-Robles A, Benrimoj SI, Gastelurrutia MA, Martinez-Martinez F, Peiro T, Perez-Escamilla B, et al. Effectiveness of a medication adherence management intervention in a community pharmacy setting: a cluster randomised controlled trial. BMJ Qual Saf. 2022;31(2):105-115. doi:10.1136/bmjqs-2020-011671
[21] Weber C, Meyer-Massetti C, Schonenberger N. Pharmacist-led interventions at hospital discharge: a scoping review of studies demonstrating reduced readmission rates. Int J Clin Pharm. 2025;47(1):15-30. doi:10.1007/s11096-024-01821-y